Please assess the completion status of the following clinical trial:

Trial Title: Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have histologically confirmed, locally advanced (unresectable) or metastatic pancreatic cancer, and have failed first-line treatment with a gemcitabine-containing regimen.~2. Patients have to be 18 years-old or older~3. Able to give signed Informed consent~4. Adequate end-organ function with laboratory parameters as follows:~   * Neutrophils: 1.5 x10\^9/L or greater~  * Plts: 100 x10\^9/L or greater~  * Hemoglobin: ≥ 9.0g/dL~  * Serum Creatinine: ≤ 1.5mg/dL~  * Bilirubin: ≤ 1.5 times the upper limit of the normal range (ULN)~  * Alanine transaminase (ALT)/Aspartate transaminase (AST): ≤ 2.5 times ULN~5. Adequate contraception: For female (or male) patients, either post-menopausal, or for pre-menopausal surgically sterilized, or willing to use an acceptable method of birth control for the duration of the study~6. Measurable or non-measurable disease by RECIST criteria~7. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2~8. Patients must be at least 3 weeks from prior therapies and must have recovered from prior toxicity~9. Life expectancy greater than 3 months~10. Willing and able to comply with the protocol requirement.~11. Patients must not have any peripheral neuropathy equal or greater than grade 2~Exclusion Criteria:~1. Chemotherapy within 3 weeks prior to enrollment~2. Radiation therapy or evidence of acute effects of radiation therapy within 2 weeks prior to enrollment.~3. Any major surgery within 4 weeks prior to enrollment~4. Peripheral neuropathy equal to or greater than grade 2~5. Clinical AIDS or known positive HIV serology~6. Evidence of concurrent, clinically evident malignancy, except inactive non-melanoma skin cancer and inactive cervical cancer diagnosed or other cancer for which the patient has been disease-free for five years~7. Unstable angina~8. New York Heart Association (NYHA) Grade II or greater congestive heart failure~9. History of myocardial infarction within 3 months~10. History of stroke within 3 months~11. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment, anticipation of need for major surgical procedure during the course of the study~12. Pregnant (positive pregnancy test) or lactating~13. Inability to comply with study and/or follow-up procedures~14. Participants with serious medical or psychiatric illness that would render chemotherapy unsafe are ineligible.~15. Participants cannot have been in another experimental drug study within 4 weeks of the first infusion of these study medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Abraxane (Type: EXPERIMENTAL): One treatment-cycle is 28 days with chemotherapy (Abraxane® 100 mg/m2) given on day 1, 8, and 15, followed by rest on week 4.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete